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The mitogen-activated protein kinases (MAPKs) are integral to the
mechanisms by which cells respond to physiological stimuli, such as
growth factors, hormones, and cytokines, and to a wide variety of
environmental stresses. The MAPKs, which are stimulated by
phosphorylation of a TXY motif in their activation loop, are
components of signal transduction cascades in which sequential
activation of protein kinases culminates in their activation and
their subsequent phosphorylation of various effector proteins that
mediate the physiological response. MAPKs are also subject to
dephosphorylation and inactivation, both by enzymes that recog-
nize the residues of the TXY motif independently and by dual
specificity phosphatases, which dephosphroylate both Tyr and
SerThr residues. We report the identification and characterization
of a novel dual specificity phosphatase. Contrary to expectation,
this broadly expressed enzyme did not inactivate MAPKs in tran-
sient cotransfection assays but instead displayed the capacity to
function as a selective activator of the MAPK Jnk, hence the name,
Jnk Stimulatory Phosphatase-1 (JSP-1). This study illustrates a new
aspect of the regulation of MAPK-dependent signal transduction
and raises the possibility that JSP-1 may offer a different perspec-
tive to the study of various inflammatory and proliferative disor-
ders associated with dysfunctional Jnk signaling.
Cells are capable of responding to various environmental cues,including physiological stimuli, such as growth factors, hor-
mones, and cytokines, and stresses, such as osmotic shock,
radiation, and ischemic injury. One of the most important
aspects of such cellular responses is the stimulation of mitogen-
activated protein kinases (MAPKs) (1–4). MAPKs are the
terminal component of a core ‘‘signaling module’’ that comprises
a series of three protein kinases. In this signaling module, MAPK
kinase kinases (MAPKKK or MEKK) phosphorylate MAPK
kinases (MAPKK or MEK) on SerThr residues with concom-
itant activation. The MAPKKs are dual specificity kinases that,
on activation, phosphorylate both the tyrosine and the threonine
residue of a conserved TXY motif in the activation loop of
MAPKs, again with concomitant activation. These signaling
modules are themselves activated in response to various stimuli,
via small GTP-binding proteins, such as those of the Ras
superfamily, and STE20-like protein kinases, such as HPK1,
MST1, NIK, and GLK, acting at the level of membrane recruit-
ment, oligomerization, and phosphorylation of MAPKKKs (1–
4). The effects of activation of these signaling modules are
manifested by the phosphorylation of a wide variety of substrates
by MAPKs, including effector protein kinases, such as MAPK-
activated protein kinases (MAPKAPs) and transcription factors,
such as the AP-1 complex (1–4).
Approximately 20 MAPKs have been identified to date in
mammalian systems, and it is thought likely that more will be
discovered (1–3). Although four major subgroups (Erk 1 and 2,
Erk 5, p38 , , , and , and Jnk 1, 2, and 3) have been
delineated, on the basis of their sequence homology and their
abilities to respond to different stimuli, additional less well
characterized MAPKs (such as MAK, MRK, and NLK) have
also been identified (3). The first major subgroup is represented
by the classical MAPKs, Erks1 and 2, in which the TXY motif
in the activation loop is TEY. Erks1 and 2 are broadly expressed
and activated in response to a wide variety of stimuli associated
with both proliferation and differentiation (1–3). The p38 group
of MAPKs, which are characterized by a TGY motif, comprise
four distinct gene products, with additional diversity introduced
through alternative mRNA splicing. These enzymes are acti-
vated by a variety of cytokines and hormones as well as in
response to environmental stress. Of particular importance to
this study is the Jnk family, characterized by a TPY motif. There
are three distinct genes, encoding Jnk1, Jnk2, and Jnk3, with
further structural diversity manifested at the level of alternative
mRNA splicing. Members of this group are predominantly
activated after exposure of cells to proinflammatory cytokines
and a variety of environmental stresses, such as radiation and
osmotic stress (1–4).
Each of the MAPK subgroups responds to distinct MAPKKs.
A combination of studies involving gene knockouts and the use
of dominant-negative mutants have implicated both MKK4 and
MKK7 in the phosphorylation and activation of Jnk (5–7).
However, differences have been ascribed to these enzymes. For
example, whereas MKK7 is primarily activated in response to
cytokines, MKK4 primarily responds to extracellular stress (4, 8).
In addition, at least in vitro, MKK4 preferentially phosphorylates
the tyrosine residue of the TPY motif of the activation loop of
the Jnks, whereas MKK7 preferentially recognizes the threonine
(9). Thus, it is possible that these enzymes may function in
cooperation to integrate signals at the level of JNK activation.
The MAPKKs are themselves activated by dual phosphorylation
of their activation loops, but unlike for the MAPKs, this occurs
on Ser and Thr residues (1–3). The MAPKKKs encompass a
broad group of kinases from several divergent families, with the
heterogeneity in these enzymes consistent with the diversity of
stimuli that lead to activation of MAPK signaling modules (1–3).
With the exception of Raf and the activation of Erks1 and 2 via
MEK12, the contribution of the various MAPKKKs to the
activation of distinct MAPK signaling modules remains unclear
(1–4, 10).
The duration and extent of MAPK activation are governed by
the balance between the activity of the MAPKKs and that of the
protein phosphatases that dephosphorylate either or both of the
Thr and Tyr residues in the TXY motif. Thus, protein phospha-
tases are also critical regulators of MAPK-dependent signaling
events. Recently, several members of the protein tyrosine phos-
phatase (PTP) family have been implicated in the dephosphor-
ylation of MAPKs (11, 12). In addition, a subgroup within the
PTP family, termed dual specificity phosphatases (DSPs), has
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been identified (13). Although DSPs display limited sequence
identity to the classical PTPs, they are characterized by the
presence of the PTP signature motif, HCXXGXXR [ST], and
share striking similarity with the PTPs in their secondary and
tertiary structures (11–15). Several of the DSPs have now been
shown to recognize MAPKs as substrate and to dephosphorylate
both the Thr and Tyr residues of the TXY activation loop motif
(12, 16, 17). Interestingly, it has been noted that coexpression of
one such DSP, MKP-1, with the MAPKKs MKK1 and MKK2,
or with Raf, lead, by an unknown mechanism, to activation of
these kinases (18). Nevertheless, even under these conditions,
MKP-1 functioned as an inhibitor of the activation of Erk and
Erk-dependent signaling (18). To date, 10 DSPs have been
identified that have the capacity to dephosphorylate and inac-
tivate MAPKs, including MKPs 1–5, VHR, hVH3B23, hVH5
M36, Pac1 and Pyst2, and which display differences in expres-
sion, tissue and subcellular distribution, and specificity for
MAPK family members (16, 17). Therefore, these MAPK
phosphatases (MKPs) represent a complex response network for
regulation of specific MAPK-dependent signaling pathways in
particular tissues and subcellular compartments after defined
stimuli.
In an effort to identify additional DSPs that may function as
regulators of MAPK-dependent signaling pathways, we searched
expressed sequence tag (EST) databases for sequences with
homology to the signature motif of members of the DSP
subfamily of PTPs. We identified and cloned several novel DSPs,
including a broadly expressed enzyme, which we have termed
JSP-1. In contrast to the established principle that DSPs are
negative regulators of MAPKs, we made the striking observation
that JSP-1 has the capacity to activate the Jnk signaling pathway
specifically (hence, Jnk Stimulatory Phosphatase-1), illustrating
a new aspect of the regulation of MAPK-dependent signal
transduction.
Material and Methods
Molecular Cloning of DSP3. We searched the National Center for
Biotechnology Information EST database (dbEST) with a
TBLASTN query of the conserved MAPK phosphatase (MKP)
active-site domain. Three ESTs were identified as containing
sequences of a novel, but incomplete, DSP. To identify the full
length open reading frame, a 3 and 5 RACE analysis was
performed on human skeletal muscle total RNA (CLONTECH)
by using the 53 RACE kit (Boehringer Mannheim) and the
manufacturer’s instructions. To obtain full length cDNA of this
DSP, now termed JSP-1, human skeletal muscle RNA (CLON-
TECH) was reverse transcribed by using Superscript II reverse
transcriptase (GIBCOBRL). The resultant DNA was used as a
template to amplify JSP-1 cDNA, encoding a protein of 184
amino acids, and the PCR product was ligated into the bacterial
expression vector pGEX-6P (Amersham Pharmacia Biotech) to
generate pGEX-6P-JSP-1.
PCR Analysis of JSP-1 Expression in Human Tissues. The human
multiple tissue cDNA panels (MTC I and MTC II) were used as
a source of cDNA (CLONTECH). The expression of JSP-1 was
analyzed by PCR by using the primer pairs JSP-1, ATG: 5-
ATGGGGAATGGGATGAACAAGATC-3 and JSP-1, 3-
ENDr: 5-CAGTCTTCTGAGAAAGGCCCAGAA-3. The cy-
cle condition for PCR was 94°C, 30 seconds, and 68°C, 1 minute,
with 23 cycles of PCR performed.
Mammalian Expression Constructs. Flag-p38, and Flag-MKK4
mammalian expression constructs were kindly provided by
Roger Davis (Howard Hughes Medical Institute, University of
Massachusetts Medical School). Myc-JNK was a gift from Jon
Cooper (Fred Hutchinson Cancer Research Center, Seattle).
To generate the N-terminally hemagglutinin-tagged JSP-1
expression construct pCGN-JSP-1-WT, pGEX-6P-JSP-1 was
used as a template to amplify the full length JSP-1 sequence
engineered to contain a 5 XbaI site and a 3 KpnI site. The PCR
product was ligated into the mammalian expression vector
pCGN.
Site-Directed Mutagenesis. Site-directed mutagenesis was carried
out by using the Quick Change protocol (Stratagene). pCGN-
JSP-1-WT was used as a template to generate the expression
constructs pCGN-JSP-1-CS, in which Cys-88 of JSP-1 was mu-
tated to Ser. The kinase-dead mutant of MKK4, MKK4-KR, was
generated by using Flag-MKK4 as template and mutating Lys-
131 to Arg.
Protein Expression and Purification. The Escherichia coli expression
constructs GST-JUN and GST-ATF2 were gifts from Roger
Davis and were expressed and purified following standard
protocols (19). GST-JSP-1 was expressed in E. coli–DH5, the
cells were lysed by sonication on ice. Triton X-100 (1% vv) was
added to the sonicate, which was then clarified and added to
glutathione-sepharose beads. JSP-1 was released from the beads
by treatment with PreScission protease (Amersham Pharmacia).
Assay of Protein Phosphatase Activity. The substrates polyGlu:Tyr
and RCML were phosphorylated with [-32P]ATP by using the
protein tyrosine kinase GST-FER (20). The stock substrate
preparations were 200 M pTyr-reduced carboxamidamethyl-
ated and maleylated lysozyme (RCML) and 80 M pTyr-
polyGlu:Tyr. Casein (Sigma) was phosphorylated with
[-32P]ATP and protein kinase A, according to the manufactur-
er’s instructions, to yield a stock substrate of 50 M pSerpThr.
Protein phosphatase assays were performed in a total volume of
100 l, in an assay buffer of 50 mM Hepes, pH 7.44 mM DTT2
mgml of BSA containing 10 l of the labeled substrate. Assays
with polyGlu:Tyr or RCML as substrate contained 100 ng of
JSP-1, whereas those using casein as substrate contained 250 ng
of JSP-1. Reactions were initiated by addition of JSP-1 and
terminated by addition of 800 l of charcoal mix, followed by
centrifugation and counting of 500 l of the supernatant in
scintillant.
Cell Culture and Transfection. COS-1 cells were maintained at 37°C
and 5% CO2 in DMEM  10% fetal bovine serum. Cells were
transfected with various expression plasmids by using the Lipo-
fectAMINE reagent, according to the manufacturer’s instruc-
tions. If no treatment was required, cells were harvested 36–48
hours after transfection. For specific treatments, cells were
switched to serum-free DMEM medium 36 hours after trans-
fection, incubated in serum-free medium overnight, then
subjected to specific stimuli and harvested. To induce activa-
tion of Jnk, cells were treated for 30 minutes with 10 ngml of
anisomycin.
Immunoprecipitation and Immunoblotting. Cells were lysed in Non-
idet P-40-containing buffer supplemented with protease and
phosphatase inhibitors. For immunoprecipitation, cell lysates
were incubated with the appropriate primary antibody for 1 hour
on ice, followed by 1-hour rotation with protein A sephorose
beads at 4°C. The beads were then washed three times in lysis
buffer and bound proteins solubilized in sample buffer. For
immunoblotting, the nitrocellulose membrane was blocked in
5% milk (or 1% BSA for anti-ACTIVE-JNK antibody) for 1
hour, then incubated with primary antibody for 1 hour at room
temperature (or overnight at 4°C for anti-ACTIVE-JNK anti-
body). After washing, the membrane was incubated with horse-
radish peroxidase-conjugated secondary antibody for 1 hour and
bound proteins detected by enhanced chemiluminescence. A
working concentration of 0.2gml was used for the anti-HA tag
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antibody 12CA5, the anti-Myc tag antibody 9E10, and the
anti-Flag tag antibody (Sigma). The stocks provided by the
manufacturers were diluted 1:5,000 for anti-ACTIVE-JNK an-
tibody (Promega) and 1:1,000 for the phospho-SEK1(Thr-261)
antibody (Cell Signaling Technology, Beverly, MA).
Immune Complex MAPK Assays. Cells were lysed in Nonidet P-40-
containing buffer supplemented with protease and phosphatase
inhibitors. The Flag-tagged p38 was immunoprecipitated with
0.75 g of anti-Flag antibody. Myc-tagged Erk1 or JNK was
precipitated with 1 g of 9E10 antibody. The immune complex
was washed twice in lysis buffer and twice in kinase assay buffer
(20 mM Pipes, pH 7.210 mM MgCl21 mM DTT0.1% Triton
X-1001 mM sodium vanadate). Reactions were initiated by
mixing the immune complex with 80 l of kinase buffer sup-
plemented with 20 M ATP10 Ci [-32P]ATP and the
appropriate substrate. GST-JUN (2 g), GST-ATF2 (2 g),
and MBP (20 g) were used as substrates for JNK, p38, and
Erk, respectively. After 10–15 minutes at 30°C, assays were
terminated by addition of 80 l of 2 SDSPAGE sample
buffer. Samples were resolved by SDSPAGE, transferred to
a nitrocellulose membrane, and the incorporation of 32P-
phosphate visualized by exposure to X-ray film and quantified
by PhosphorImage.
Results
Molecular Cloning of JSP-1. To identify novel DSPs involved in the
regulation of MAPK family members, we searched the National
Center for Biotechnology Information dbEST with a TBLASTN
query of the conserved MAPK phoshatase active site domain.
We identified three ESTs, AA374753, AA 411671, and H82446,
as containing sequences of an incomplete DSP. The full length
open reading frame, identified by 3 and 5 RACE analysis on
human skeletal muscle total RNA as a template, encoded 184
amino acids (Fig. 1) and was designated JSP-1 (defined below).
JSP-1 displayed 33–40% identity (58% similarity) to the catalytic
domains of the known MKPs, MKP4, MKP5, Pyst1, and hVH5,
and contained both the conserved signature motif of the PTP
family, HC(X)5R, and AYLM, a conserved motif of MKPs.
JSP-1 Is Broadly Expressed in Human Tissues. We examined the tissue
distribution of JSP-1 by Northern blot analysis and found two
major transcripts, of 4.0 and 1.35 kb, that were broadly expressed.
In addition, we performed PCR analysis by using the Multiple
Tissue cDNA panels I and II (CLONTECH) as templates. PCR
products were detected in all tissues examined, with highest
expression observed in heart, placenta, lung, liver, kidney, and
pancreas (data not shown), indicating that in humans, JSP-1 is
broadly expressed in a variety of tissues.
JSP-1 Is a Dual Specificity Phosphatase. To demonstrate that JSP-1
exhibits intrinsic DSP activity, we expressed it as a GST-fusion
protein in E. coli. The fusion protein was purified over gluta-
thione sepharose and the GST tag removed by PreSission
protease cleavage. The activity of purified JSP-1 was then
determined by using a variety of substrates, including both
proteins and peptides phosphorylated on Tyr residues, such as
polyGlu:Tyr and RCML, and proteins phosphorylated on Ser
Thr residues, such as casein and histone. JSP-1 readily dephos-
phorylated tyrosyl-phosphorylated substrates. The specific ac-
tivities against polyGlu:Tyr (80 nmolminmg) and RCML (144
nmolminmg) were similar to those observed for other PTPs
(21). However, although JSP-1 dephosphorylated SerThr res-
idues in proteins, it did so with a much lower specific activity, for
example 1 nmolminmg for protein kinase A-labeled casein.
Similar preference for tyrosine-phosphorylated substrates has
been reported for the DSP VHR (22). Nevertheless, it remains
to be determined whether this reflects weaker intrinsic SerThr
phosphatase activity of JSP-1 or simply that the substrates tested
to date are suboptimal for this phosphatase.
JSP-1 Specifically Activates the Jnk Signaling Pathway. Because
many DSPs have been shown to dephosphorylate and inactivate
MAPKs, we examined the effects of JSP-1 on different members
Fig. 1. Nucleotide and predicted peptide sequence of JSP-1.
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of the MAPK family. Plasmids encoding hemagglutinin-tagged
JSP-1 constructs and epitope-tagged Jnk, epitope p38, or Erk1
MAPKs were cotransfected in COS cells. Each kinase was
immunoprecipitated, and its activity was measured in an im-
mune-complex kinase assay. To our surprise, we did not detect
inhibition of epidermal growth factor-induced Erk or inhibition
of Cdc42 (V12)-induced Jnk or p38 in these assays (Fig. 2). In
contrast, we observed that ectopic expression of JSP-1 led to a
dose-dependent increase in the activity of coexpressed Jnk,
whereas the activities of Erk1 and p38 were not significantly
affected (Fig. 3). Furthermore, the extent of activation of Jnk by
JSP-1 was similar to that observed in response to the physio-
logical stimulus sorbitol (Fig. 3B). Expression of an inactive
mutant form of JSP-1, in which the active site cysteine (Cys-88)
was changed to serine, did not lead to activation of Jnk,
indicating that the phosphatase activity of JSP-1 is required for
this effect (Fig. 3B). It has been shown that dual phosphorylation
of both the Thr and Tyr residues in the TPY motif of the
activation loop of Jnk is required for activation. To test whether
JSP-1-induced activation of Jnk correlated with increased phos-
phorylation of these sites, we coexpressed Flag-tagged Jnk with
either a control vector, wild-type JSP-1 or the C3S mutant form
of JSP-1 in COS cells. The phosphorylation status of JNK was
then examined by immunoblotting with the anti-ACTIVE-JNK
antibody (Promega), which specifically recognizes the dual phos-
phorylated TPY motif. We observed that overexpression of
wild-type JSP-1 increased the phosphorylation of coexpressed
JNK, whereas the inactive C3S mutant form of the phosphatase
did not. Immunoblotting with an antibody to the Myc tag
illustrated that equivalent quantities of JNK were present in each
sample (Fig. 3C). On the basis of these data, we refer to this
phosphatase as Jnk-Stimulatory Phosphatase-1 (JSP-1).
Fig. 2. JSP-1 did not inactivate MAP kinases. Flag-tagged Jnk (A) or Flag-
tagged p38 (B) was coexpressed with a control vector (lane 1) or an active
mutant form of Cdc42 (V12) in the absence (lane 2) or presence (lane 3) of
JSP-1. Cells were serum starved overnight before harvesting. (C) Myc-tagged
Erk was coexpressed with a control vector (lanes 1 and 2) or with JSP-1 (lane
3). Cells were serum starved overnight and harvested without stimulation
(lane 1) or following stimulation with epidermal growth factor for 25 minutes
before harvesting (lanes 2 and 3). The kinase activity of Jnk, p38, and Erk was
determined by immunoprecipitation of the kinases and immune-complex
assays with GST-Jun, GST-ATF2, or myelin basic protein (A Upper, B Upper, and
C Upper, respectively) as substrate. The level of Jnk, p38, and Erk in each
reaction was determined by immunoblotting with the anti-Flag antibody (A
Lower and B Lower) or the anti-Myc antibody, 9E10 (C Lower).
Fig. 3. JSP-1 specifically activated Jnk. (A) A control vector (lane 1) or 0.2, 0.5,
1, or 2 g (lanes 2–5) of plasmid encoding JSP-1 were each cotransfected with
0.5 g of plasmid encoding Myc-tagged Jnk (Upper), Flag-tagged p38 (Mid-
dle), or Myc-tagged Erk (Lower), respectively. The total amount of DNA in each
transfection was adjusted to 2.5 g with control vector. The kinase activities
of Jnk, p38, or Erk were determined by immunoprecipitation of the kinase and
immune-complex assays with GST-Jun (Upper), GST-ATF2 (Middle), or myelin
basic protein (Lower) as substrate. The level of Jnk, p38, or Erk in each kinase
reaction was determined by immunoblotting by using anti-Myc antibody 9E10
(Upper and Lower) or the anti-Flag antibody (Middle). (B and C) Myc-tagged
Jnk was coexpressed with control vector (lane 1), wild-type JSP-1 (lane 2), or
the inactive C3S mutant form of JSP-1 (lane 3). In addition, cells expressing
Myc-tagged Jnk were stimulated with 500 mM sorbitol (B, lane 4). Jnk activity
was determined by the immune-complex kinase assay (B) or by immunoblot-
ting with the anti-ACTIVE-JNK antibody (C). The amount of Jnk in each sample
was determined by immunoblotting using the anti-Myc antibody 9E10.
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Activation of Jnk by JSP-1 Is Associated with Activation of MKK4. The
activity of Jnk is controlled by the coordinated actions of positive
regulators, such as the MAPKKs, and negative regulators,
including MKP-type protein phosphatases. Stimuli such as os-
motic stress and various cytokines activate Jnk primarily via
activation of MAPKKs, such as MKK4, whereas heat shock and
oxidative stress have been shown to prevent inactivation of Jnk
by phosphatases (23). Similarly, the stimulatory effects of JSP-1
on Jnk activation could be manifested either through activation
of a MAPKK or by prevention of the inactivation of Jnk. To
distinguish between these possibilities, we compared the inacti-
vation rate of ectopically expressed Jnk in cells overexpressing
either JSP-1 or a vector control. Jnk was activated by pretreating
cells with anisomycin for 30 minutes, then the cells were treated
with rotenone, an inhibitor of the respiratory chain, and deoxy-
glucose, an inhibitor of glycolysis, to block ATP synthesis. Under
these conditions, the high intracellular ATPase activity leads to
a rapid decrease in the levels of cellular ATP, blocking the de
novo activation of Jnk by other kinases (23). We observed that
Jnk activity, determined by immune-complex kinase assay, was
reduced by 70% within 5 minutes of ATP depletion and was
essentially completely inactivated within 30 minutes. This rate of
inactivation of Jnk was the same in the presence or absence of
JSP-1, indicating that JSP-1 is unlikely to exert its effects by
preventing inactivation of Jnk.
We then tested whether overexpression of JSP-1 led to
activation of kinases upstream of Jnk. MKK4 phosphorylates
and activates Jnk both in vitro and in vivo (9, 12, 24) and is itself
activated through phosphorylation by an upstream MAPKKK
(5). Because activation of MKK4 depends on phosphorylation on
its activation loop, immunoblot analysis was performed with an
antibody that specifically recognizes MKK4 phosphorylated on
Thr-261 (antiphopho-SEK), as an indirect measurement of
MKK4 activity. MKK4 was coexpressed with either wild-type
JSP-1, the C3S inactive mutant form of JSP-1, or a vector
control and the phosphorylation level of MKK4 determined by
immunoblotting with antiphopho-SEK antibody. Under condi-
tions used in this study, the antiphospho-SEK antibody detected
ectopically expressed MKK4, but not the endogenous enzyme,
even after anisomycin treatment (data not shown). Enhanced
phosphorylation of MKK4 was detected in cells coexpressing
MKK4 and wild-type JSP-1, but not in cells coexpressing MKK4
and either the C3S mutant form of JSP-1 or the vector control
(Fig. 4A). Furthermore, JSP-1 activated MKK4 to an extent
similar to that observed in response to the physiological stimulus
sorbitol (Fig. 4A). Thus, overexpression of JSP-1 led to activa-
tion of MKK4, and this activation depends on the phosphatase
activity of JSP-1.
To investigate further whether MKK4 is required for JSP-1-
induced activation of Jnk, we coexpressed myc-tagged Jnk with
a control vector, wild-type JSP-1, or JSP-1, together with a
dominant-negative form of MKK4 (MKK4-KR) in COS-1 cells.
Jnk activity was measured by immune-complex kinase assays in
cell lysates. We observed that overexpression of JSP-1 caused a
2.5-fold increase in Jnk activity, which was almost completely
abolished by coexpression of the dominant-negative MKK4.
Immunoblots using antibodies to Myc-Jnk or hemagglutinin-
JSP-1 demonstrated that the differences we observed in Jnk
activity did not result from variations in the levels of Jnk or JSP-1
protein (Fig. 4B).
Discussion
The MAPKs are critical regulators of signaling pathways under-
lying cellular responses to environmental cues that alter prolif-
eration, differentiation, and survival. In addition, the MAPKs
are of fundamental importance in embryonic development.
Great progress has been made in defining the various three-
tiered protein kinase cascades that culminate in activation of
MAPKs and in characterizing both the mechanisms by which
they are triggered in response to defined stimuli and those by
which they effect a physiological response (1–4). Recently,
attention has also focused on the protein phosphatases as
regulators of these signaling pathways (11–13). The MAPKs are
activated by phosphorylation of the Thr and Tyr residues of the
TXY motif in their activation loop. Inactivation is mediated in
vivo both by single-specificity phosphatases, acting indepen-
dently on the residues of the TXY motif, and members of a
subfamily of the PTPs, termed DSPs, which have the capacity to
dephosphorylate both Tyr and SerThr residues in their target
substrates (16, 17). In short, it now appears that the regulation
of MAPKs that is exerted at the level of the protein phosphatases
is as sophisticated as that mediated by the protein kinases. In this
study, we reveal a further level of complexity to the regulation
of MAPK-dependent signaling pathways. In a search for addi-
tional DSPs with the ability to down-regulate MAPK function,
we identified an enzyme now termed JSP-1. To our surprise,
rather than catalyzing the dephosphorylation and inactivation of
MAPKs, we have observed that this DSP has the capacity to
function as a specific activator of the Jnk signaling pathway.
Utilizing the full length peptide sequence of JSP-1 and an
advanced TBLASTN query for Mus musculus dbEST sequences in
the National Center for Biotechnology Information database, we
identified the EST AA103595 as containing sequences homol-
ogous to the N-terminal half of human JSP-1. A BLAST analysis
of the Mus musculus dbEST database searching with AA103595
allowed us to identify another overlapping EST, AW413206,
which contains the carboxyl-terminal portion of murine JSP-1
(mJSP-1). The combined sequence from both ESTs AA103595
and AW413206 encodes a protein that is closely related to
Fig. 4. JSP-1 activated JNK through activation of MKK4. (A) Flag-tagged
MKK4 was coexpressed with a control vector (lane 1), plasmid encoding
wild-type JSP-1 (lane 2), or the inactive C3S mutant form of JSP-1 (lane 3). In
addition, cells expressing Flag-tagged MKK4 were stimulated with 500 mM
sorbitol (lane 4). Cell lysate was resolved by SDSPAGE, and the MKK4 activity
was measured by immunoblotting with antiphospho-SEK antibody (Upper).
The amount of MKK4 in each lane was determined by immunoblotting with
anti-Flag antibody (Lower). (B) Myc-tagged Jnk was coexpressed with control
vector (lane 1) or hemagglutinin-tagged wild-type JSP-1 in the absence (lane
2) or presence of the inactive K3R mutant form of MKK4 (lane 3). Jnk activity
was determined by immune-complex kinase assay (Top). The amount of Jnk in
each reaction was determined by immunoblotting with the anti-Myc antibody
9E10 (Middle), and the expression of JSP-1 was determined by immunoblot-
ting with the 12CA5 antibody (Bottom).
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human JSP-1 in the N-terminal 169 residues (95% similarity),
suggesting that this combined sequence may represent the
murine homolog of human JSP-1. In searching the GenBank
nonredundant database with a TBLASTN query by using the
full-length peptide sequence of human JSP-1, we also identified
a database entry AK000383, which is a partial human cDNA
encoding a peptide displaying 100% identity to residues 65–169
of human JSP-1. The C-terminal 36 residues of sequence trans-
lated from AK000383 were different from the C terminus of
human JSP-1 but highly related to that of murine JSP-1 (78%
identity). Therefore, AK000383 may represent an alternatively
spliced variant of human JSP-1. We also searched the dbEST
database with JSP-1 peptide sequence looking for matches with
ESTs from other species. Several were found, including Rat
[BF549803, 92% identity (128139) and 98% similarity (137
139)], Xenopus [AW646139, 74% identity (128171) and 86%
similarity (149171)], Drosophila [BF495653, 50% identity (83
163) and 72% similarity (119163)], and zebrafish [BE557484,
66% identity (99148) and 83% similarity (125148)]. In light of
the extensive similarity between JSP-1 and these ESTs, it is
possible that they may represent homologs of JSP-1, consistent
with an important biological function for the enzyme that may
be conserved across species.
JSP-1 is a small DSP that is reminiscent of one of the initially
characterized members of the family, VHR (22). It lacks the
cdc25-homology domains found in the noncatalytic segments of
previously characterized MKPs, such as MKP-1. These domains
have been implicated in substrate docking and specificity deter-
mination in the MKPs (16, 17, 25). Nonetheless, JSP-1 does
display specificity in function. Characterization of its enzymatic
activity revealed preferential dephosphorylation of tyrosyl res-
idues in proteins, as previously noted for VHR (22). In fact, the
activity of JSP-1 toward artificial pTyr-containing substrates in
vitro is similar to that observed for other members of the family
(21). However, although the activity of JSP-1 was low toward the
pSerpThr-containing proteins that have been tested as sub-
strates to date in vitro, one should not conclude that the
phosphatase will recognize pTyr residues preferentially in vivo.
Many examples have now been documented in which members
of the PTP family display specificity in their recognition of target
substrates (12). Therefore, a complete characterization of the
activity of JSP-1 and a definition of its preference for phosphor-
ylated residues in proteins will require the identification of its
physiological substrates.
Our data illustrate that JSP-1 has the potential to display
specificity in a cellular context, in that its expression led to
activation of Jnk without altering the activity of Erk or p38
MAPKs. Overexpression of JSP-1 also led to the activation of
MKK4, a MAPKK that functions upstream of Jnk. Furthermore,
a dominant-negative mutant form of MKK4 abolished JSP-1-
induced activation of Jnk. These data suggest that JSP-1 does not
exert its effects directly on Jnk but support a site of action of the
phosphatase upstream of MKK4. Although overexpression of
MKK4 has been reported to activate both JNK and p38 (4), we
observed that only JNK was activated after overexpression of
JSP-1. Whether this reflects a limited activation of MKK4 by
JSP-1 that is sufficient for activation of Jnk but not sufficient for
activation of p38 remains to be determined. Interestingly, a
similar situation was reported for MLK3, a MAPKKK that
functions upstream of MKK4 (26). Although MLK3 is an
activator of MKK4, its expression results only in the activation
of Jnk and not p38 (27). Many different phosphorylation events
have the potential to regulate the Jnk signaling pathway up-
stream of MKK4, including a large number of MAPKKKs such
as MEKK1, MEKK4, and the mixed lineage kinases, as well as
Ste20-like kinases that function in linking MAPK cascades to
external stimuli. Further insights into how JSP-1 stimulates Jnk
signaling will be gained after identification of the physiological
substrates and regulators of this phosphatase.
The activation of Jnk has been implicated in a number of
important physiological processes, from embryonic morphogen-
esis to cell survival and apoptosis. Jnk signaling has also been
linked to human disease conditions, including tumor develop-
ment, cardiac hypertrophy, ischemiareperfusion injury, diabe-
tes, hyperglycemia-induced apoptosis, and several neurodegen-
erative disorders (1–4). Thus, the Jnks are viewed as exciting
candidates for therapeutic intervention. Our studies reveal a
novel aspect of the regulation of Jnk-signaling, a DSP that may
function in the activation of Jnk without effect on Erk and p38
MAPKs. Therefore, it will be exciting to see whether, with
continued investigation, JSP-1 may also be considered as a target
for therapeutic intervention in human disease.
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